NOX 2.86% 7.2¢ noxopharm limited

"A Dose Escalation and Dose Expansion Study of NOX66 Plus...

  1. 6,848 Posts.
    lightbulb Created with Sketch. 2536
    "A Dose Escalation and Dose Expansion Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma"

    Another Phase I trial. Wow this must be approaching something of a record I have counted 7 phase I trial slated on the official score board at clincaltrials.gov. Not even including the Lupin trials as they are on another site. So that is eight. Strange that since the invention of NOX66 way back in 2012 they are still pumping out phase I trial and to date still have not one large phase ii trial completed. Clearly in very safe hands....very safe hands indeed. At this snails pace rate one could believe in this company for ever.

    And remember we are just talking about the new delivery system not the active ingredient which has been on the score board for 30 plus years.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
7.2¢
Change
0.002(2.86%)
Mkt cap ! $21.04M
Open High Low Value Volume
7.2¢ 7.2¢ 7.2¢ $1.367K 18.99K

Buyers (Bids)

No. Vol. Price($)
1 72463 6.9¢
 

Sellers (Offers)

Price($) Vol. No.
7.2¢ 8810 1
View Market Depth
Last trade - 15.33pm 26/07/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.